Versant Venture Capital VI, L.P., 10% Owner at Akero Therapeutics, Inc. (AKRO), sold 778,764 shares at $22.58 ($18.8M) on 2019-12-27, disclosed to the SEC on 2019-12-31.
Open-market sale of $18.8M AKRO by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.58 | 33,256 | $751K | 4.0% |
| 2 | $22.58 | 33,256 | $751K | 4.0% |
| 3 | $24.39 | 338,919 | $8.3M | 43.9% |
| 4 | $24.39 | 338,919 | $8.3M | 43.9% |
| 5 | $23.48 | 17,207 | $404K | 2.1% |
| 6 | $23.48 | 17,207 |
| $404K |
| 2.1% |
| Total | $24.20 avg | 778,764 | $18.8M | 100% |
| Filing → |
| GLUE | SELL | 2024-10-30 | $2.8M | — | Filing → |
| GLUE | SELL | 2024-09-24 | $14.8M | — | Filing → |
| TPST | SELL | 2024-08-12 | $1.4M | — | Filing → |